[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"phobia-social\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:phobia-social":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100489126","phase-4-investigating-the-effects-of-cannabidiol-on-social-anxiety-disorder-100489126",false,"NCT05649059","Investigating the Effects of Cannabidiol on Social Anxiety Disorder","CAN-SAD","Inclusion Criteria:\n\n* Ability and willingness to provide written informed consent.\n* Sufficiently fluent in English to participate in the trial.\n* Between 18-55 years of age (inclusive).\n* Right-hand dominant.\n* Current medications are stable for past 30 days (no changes to dose or frequency).\n* Negative result on pregnancy test (if female).\n* Negative result on urine drug screening.\n* Liebowitz Social Anxiety Scale (LSAS ≥ 60).\n\nExclusion Criteria:\n\n* History of bipolar disorder, schizophrenia, psychosis, delusional disorders.\n* History of eating disorder within past 6 months.\n* History of any traumatic brain injury.\n* Currently diagnosed with diabetes mellitus.\n* Presence of severe medical illness that would prevent completion of study procedures.\n* Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia).\n* History of substance use disorder within past 6 months (other than nicotine and caffeine).\n* Use of any cannabis-containing products in past 30 days (CBD or THC).\n* Use of benzodiazepines in past 2 weeks.\n* Use of alpha- or beta-blockers in past week.\n* History of claustrophobia.\n* Contraindications for MRI (e.g.; shrapnel).\n* Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures.\n* Use of concomitant medication that has a strong interaction with CBD.\n* History of liver disease.\n* History of hypersensitivity to cannabinoids.\n* History of hypersensitivity to sesame seed oil.\n* Currently breastfeeding (if female).","ALL","18 Years","55 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).",[27],"Phobia, Social",[29,30,31],"Social Anxiety Disorder","Cannabidiol","fMRI","RECRUITING","2025-11-25",{"date":35,"type":36},"2025-12-03","ACTUAL",{"date":38,"type":36},"2025-07-10",{"date":40,"type":21},"2026-09",{"name":42,"class":43},"Massachusetts Institute of Technology","OTHER"]